The global transplantation market is expected to generate $30,117.5 million revenue by 2030, advancing at a considerable rate of 9.2% during 2021–2030. Artificial organs, along with research and development in the transplantation of genetically modified animal organs into the human body, are creating opportunities for the companies operating in the market.
Moreover, the improvements in the processes of organ transportation, organ preconditioning, pre-transplant treatment, and deceased organ prevention are fueling the growth. For instance, three children, who received kidney transplants in California, may never have to take anti-rejection medication, due to the adoption of a new procedure that eliminates the need for lifetime immunosuppression.
The majority of the transplant procedures are carried out in hospitals; however, patients and donors are also becoming aware of transplantation centers with specialty surgeons and other staff members. These centers have access to a large network of donors and patients and conduct research and development for innovative approaches and higher success rates.
Tissue transplantation is the major application in the transplantation market due to the increasing transplants of blood vessels, corneas, heart valves, ligaments, skin, bones, and tendons. This increase is due to the rising number of accidents, along with the surging number of people engaging in sports activities, which often lead to tissue injuries, especially in the bones and the skin. Moreover, the increase in the use of tissue products, such as orthobiologics, which help in healing tissues, minimizing pain, and restoring normal functioning, is propelling the market growth.
North America held the largest share of the revenue, of around 40%, in 2021, with the U.S. being the larger market. Various initiatives related to transplantation have been introduced in the U.S. to improve the access to viable organs across the country. Such initiatives include the Pluralist Program of UC Davis Health and the Kidney Transplant Program of the Medical Center of UC Davis Health.
The APAC region is expected to be the fastest-growing market during the forecast period owing to the rising incidence of chronic diseases due to the large population and its rapid aging. Additionally, the medical tourism sector is growing in the region, as getting a treatment here is cost-effective compared to in North America and Europe.
China and Japan are the major transplantation markets in the region, while India will also display significant growth during the forecast period. The country has a high prevalence of diabetes and obesity, which often lead to organ failures. Moreover, the number of accidents is increasing, thus leading to a surge in the need for skin and bone transplants.
In recent years, organizations operating in the market have been involved in launching new products, collaborations, partnerships, mergers and acquisitions, and research and development. For instance, in April 2022, TransMedics received the FDA’s premarket approval for its OCS heart system, for use with organs from donors after circulatory death (DCD).
Major players operating in the transplantation market are Abbvie Inc., Arthrex Inc., BioLife Solutions Inc., TransMedics Inc., Medtronic plc, Novartis AG, Teva Pharmaceuticals Industries Ltd., Veloxis Pharmaceuticals A/S, Stryker Corporation, and Zimmer Biomet Holdings Inc.